BNGO vs. PRE, RPID, OMIC, HLTH, AXDX, SEER, AKYA, TARA, FHLT, and PTWO
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Singular Genomics Systems (OMIC), Cue Health (HLTH), Accelerate Diagnostics (AXDX), Seer (SEER), Akoya Biosciences (AKYA), Protara Therapeutics (TARA), Future Health ESG (FHLT), and Pono Capital Two (PTWO). These companies are all part of the "medical" sector.
Prenetics Global (NASDAQ:PRE) and Bionano Genomics (NASDAQ:BNGO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.
Prenetics Global has a beta of -0.28, indicating that its share price is 128% less volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.
In the previous week, Bionano Genomics had 1 more articles in the media than Prenetics Global. MarketBeat recorded 3 mentions for Bionano Genomics and 2 mentions for Prenetics Global. Bionano Genomics' average media sentiment score of 0.00 beat Prenetics Global's score of -0.16 indicating that Prenetics Global is being referred to more favorably in the media.
Bionano Genomics received 157 more outperform votes than Prenetics Global when rated by MarketBeat users. However, 83.33% of users gave Prenetics Global an outperform vote while only 64.80% of users gave Bionano Genomics an outperform vote.
Prenetics Global has higher earnings, but lower revenue than Bionano Genomics. Prenetics Global is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Prenetics Global presently has a consensus target price of $9.00, indicating a potential upside of 55.07%. Bionano Genomics has a consensus target price of $4.00, indicating a potential upside of 250.88%. Given Prenetics Global's higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Prenetics Global.
25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by insiders. Comparatively, 2.4% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Prenetics Global has a net margin of -193.60% compared to Prenetics Global's net margin of -605.26%. Bionano Genomics' return on equity of -11.15% beat Prenetics Global's return on equity.
Summary
Prenetics Global beats Bionano Genomics on 11 of the 18 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
